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Resolution of Clinical Signs of Ventilator-Associated Pneumonia in
Trauma Patients
Abstract
Objectives: The ATS/IDSA Ventilator-Associated Pneumonia (VAP) guidelines suggest that clinical
improvement of VAP should be apparent within 3–6 days. This study evaluated resolution of clinical signs of
VAP in trauma patients after diagnosis.
Methods: Critically injured adults admitted to the trauma intensive care unit (ICU) from June 1, 2006, to
December 31, 2007, and subsequently given a diagnosis of VAP were retrospectively assessed. Clinical signs,
including derangements of maximum temperature (Tmax), white blood cell (WBC) count, and PaO2/FiO2,
were evaluated on days 1–16 after VAP diagnosis. Data are presented as mean ± SD unless otherwise stated.
Clinical parameters after VAP were compared using repeated-measures ANOVA with the Tukey test for
multiple comparisons.
Results: A total of 82 patients were identified. Data for the 34 patients without concurrent infections are
presented. Demographic data include: Age 46 ± 17 years; 71% men; 94% blunt trauma; median (IQR) Injury
Severity Score 29.5 (24–38); duration of mechanical ventilation 33 ± 27 days; ICU length of stay (LOS) 39 ±
25 days; hospital LOS 53 ± 33 days. Clinical signs following VAP diagnosis: Tmax (°F): Day 1=101.8 ± 1.3,
Day 3=101.1 ± 1.1, Day 6=101.1 ± 1.4, Day 16=100.1 ± 3. Compared to Day 1, there was a significant
reduction in Tmax at days 10, 11, 12, 13, 14, and 16 (p<0.05 for all). WBC count (cells per microliter): day 1
= 12.9 ± 5, day 3 = 13.7 ± 5, day 6 = 14.4 ± 5, and day 16 = 13.8 ± 6. There was no significant difference in
WBC on days 1–16 (p=0.42). PaO2/FiO2: day 1 = 232 ± 108, day 3 = 200 ± 87, day 6 = 218 ± 104, day 16 =
246 ± 126. Differences in PaO2/FiO2 on days 1–16 did not reach statistical significance (p=0.06).
Conclusion: Improvement of clinical parameters after a VAP diagnosis is delayed in trauma patients.
Alternative methods for determining resolution should be investigated. Published in To be published in
Critical Care Medicine’s December 2009 supplement.
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Clinical Suspicion of VAP
Fiberoptic Bronchoscopy with BAL
<7 days in ICU:
Ampicillin/sulbactam
3g IV q6h
>7 days in ICU:
Vancomycin 20mg/kg IV q12h 
+
Cefepime 2g IV q8h
NGTD/ <100,000 cfu/mL 100,000 cfu/mL
Discontinue 
antibiotic therapy Expand coverage if 
organisms not covered
























Duration of mechanical ventilation, days (mean + SD)  32 + 32
ICU LOS, days (mean + SD)  37 + 31











Age, years (mean ± SD)  46 + 17 43 + 17 0.39
Males, number (%)  24/10 (71) 36/13 (73) 0.97
Blunt Injury %  32/2 (94) 39/10 (80) 0.11
Injury Severity Score, median (IQR) 29.5 (24 to 38) 34 (26 to 42) 0.19
Duration of MV, days (mean + SD)  33 + 27 32 + 36 0.49
ICU LOS, days (mean + SD)  39 + 25 36 + 34 0.21
Hospital LOS, days (mean + SD  53 + 33 49 + 42 0.11






























Days Following VAP Diagnosis





























Days Following VAP Diagnosis


















Days Following VAP Diagnosis












CLINICAL PARAMETERS OVER TIME
20
Parameter Day 1 Day 3 P Value
WBC (cells/μL) 12.9 + 5 13.7 + 5 NS
Tmax (°F) 101.8 + 1.3 101.1 + 1.1 NS
PaO2/FIO2  231.6 + 107.9 200 + 87 NS
Parameter Day 1 Day 6 P Value
WBC (cells/μL) 12.9 + 5 14.4 + 5 NS
Tmax (°F) 101.8 + 1.3 101.1 + 1.4 NS
PaO2/FIO2 () 231.6 + 107.9 218 + 104 NS
CONCLUSION
• Clear, rapid resolution of clinical signs of VAP 
not seen in critically injured trauma patients
• Future studies should explore other methods 
to determine clinical response to VAP in 
trauma patients
21
